Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 545

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

Itzykson, Raphaël, Kosmider, Olivier, Renneville, Aline, Gelsi-Boyer, Véronique, Meggendorfer, Manja, Morabito, Margot, Berthon, Céline, Adès, Lionel, Fenaux, Pierre, Beyne-Rauzy, Odile, Vey, Norbert, Braun, Thorsten, Haferlach, Torsten, Dreyfus, François, Cross, Nicholas C.P., Preudhomme, Claude, Bernard, Olivier A., Fontenay, Michaela, Vainchenker, William, Schnittger, Susanne, Birnbaum, Daniel, Droin, Nathalie, Solary, Eric·2013·Journal of Clinical Oncology

Abstract

Purpose: Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have been associated with poor prognosis in univariable analyses. We developed and validated a prognostic score for overall survival (OS) based on mutational status and standard clinical variables. Patients and Methods: We genotyped ASXL1 and up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription (RUNX1, NPM1, TP53), and signaling (NRAS, KRAS, CBL, JAK2, FLT3) regulators in 312 patients with CMML. Genotypes and clinical variables were included in a multivariable Cox model of OS validated by bootstrapping. A scoring system was developed using regression coefficients from this model. Results: ASXL1 mutations (P < .0001) and, to a lesser extent, SRSF2 (P = .03), CBL (P = .003), and IDH2 (P = .03) mutations predicted inferior OS in univariable analysis. The retained independent prognostic factors included ASXL1 mutations, age older than 65 years, WBC count greater than 15 ×10 9 /L, platelet count less than 100 ×10 9 /L, and anemia (hemoglobin < 10 g/dL in female patients, < 11g/dL in male patients). The resulting five-parameter prognostic score delineated three groups of patients with median OS not reached, 38.5 months, and 14.4 months, respectively (P < .0001), and was validated in an independent cohort of 165 patients (P < .0001). Conclusion: A new prognostic score including ASXL1 status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes. Based on concordance analysis, this score appears more discriminative than those based solely on clinical parameters.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.47.3314

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 545

Metadata

Authors
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N. C. P., Preudhomme, C., Bernard, O. A., Fontenay, M., Vainchenker, W., Schnittger, S., Birnbaum, D., Droin, N., & Solary, E.
Venue
Journal of Clinical Oncology
Published
2013-07-01
Volume
31
Issue
19
Pages
2428-2436
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2149089431
Cited by
545
References
7
FWCI
36.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2012.47.3314
The paper
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N. C. P., Preudhomme, C., Bernard, O. A., Fontenay, M., Vainchenker, W., . . . Solary, E. (2013). Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.47.3314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.